Effectiveness of sitagliptin in Cystic Fibrosis with impaired glucose tolerance
Brief description of study
Patients with Cystic Fibrosis often suffer from glucose intolerance.
This study will evaluate how effective sitagliptin, a DPP-IV inhibitor, is at improving glycemic control in the Cystic Fibrosis population. Participants will complete baseline testing, then will be asked to take a once-daily pill for 6-months before completing follow-up testing. Participants are compensated $650 for completing study procedures.
Detailed description of study
This trial will evaluate the participant's metabolic response pre- and post-treatment using a Mixed Meal Tolerance Test and a Glucose Potentiated Arginine Test. After successful Screening, patients will undergo metabolic testing on two separate days before starting study drug or placebo. After 6-months, participants will return for two days of follow-up testing. Participants are compensated $650 for time and inconvenience of Study Visits.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Cystic fibrosis,Glucose Intolerance,Cystic fibrosis related diabetes,diabetes mellitus related to CF,Indeterminant Glucose Tolerance,CF,CF
-
Age: Between 18 Years - 55 Years
-
Gender: All
Updated on
08 Jul 2023.
Study ID: 818014
